JP2018527330A - 線維症の処置 - Google Patents

線維症の処置 Download PDF

Info

Publication number
JP2018527330A
JP2018527330A JP2018504650A JP2018504650A JP2018527330A JP 2018527330 A JP2018527330 A JP 2018527330A JP 2018504650 A JP2018504650 A JP 2018504650A JP 2018504650 A JP2018504650 A JP 2018504650A JP 2018527330 A JP2018527330 A JP 2018527330A
Authority
JP
Japan
Prior art keywords
irap
fibrosis
alkyl
mice
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018504650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527330A5 (cg-RX-API-DMAC7.html
Inventor
シュウ イーン チャイ
シュウ イーン チャイ
ロバート ウィドップ
ロバート ウィドップ
トレイシー ガスパリ
トレイシー ガスパリ
ヒュイ ウェン リー
ヒュイ ウェン リー
Original Assignee
モナシュ ユニバーシティー
モナシュ ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903035A external-priority patent/AU2015903035A0/en
Application filed by モナシュ ユニバーシティー, モナシュ ユニバーシティー filed Critical モナシュ ユニバーシティー
Publication of JP2018527330A publication Critical patent/JP2018527330A/ja
Publication of JP2018527330A5 publication Critical patent/JP2018527330A5/ja
Priority to JP2020127888A priority Critical patent/JP7457360B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018504650A 2015-07-30 2016-07-29 線維症の処置 Withdrawn JP2018527330A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020127888A JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903035 2015-07-30
AU2015903035A AU2015903035A0 (en) 2015-07-30 Fibrotic treatment
PCT/AU2016/050681 WO2017015720A1 (en) 2015-07-30 2016-07-29 Fibrotic treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020127888A Division JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置

Publications (2)

Publication Number Publication Date
JP2018527330A true JP2018527330A (ja) 2018-09-20
JP2018527330A5 JP2018527330A5 (cg-RX-API-DMAC7.html) 2019-03-07

Family

ID=57883919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018504650A Withdrawn JP2018527330A (ja) 2015-07-30 2016-07-29 線維症の処置
JP2020127888A Active JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置
JP2022199857A Pending JP2023030022A (ja) 2015-07-30 2022-12-15 線維症の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020127888A Active JP7457360B2 (ja) 2015-07-30 2020-07-29 線維症の処置
JP2022199857A Pending JP2023030022A (ja) 2015-07-30 2022-12-15 線維症の処置

Country Status (8)

Country Link
US (5) US10100311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328384B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018527330A (cg-RX-API-DMAC7.html)
AU (1) AU2016301113B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017028C (cg-RX-API-DMAC7.html)
HK (1) HK1256423A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201808478RA (cg-RX-API-DMAC7.html)
WO (1) WO2017015720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294721A4 (en) * 2015-05-08 2018-11-07 Monash University 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
EP3328384B1 (en) 2015-07-30 2020-07-29 Monash University Fibrotic treatment
US11331368B2 (en) * 2017-07-17 2022-05-17 Monash University Angiotensin receptor agonists and uses thereof
EP3902460A4 (en) * 2018-12-28 2023-01-11 The General Hospital Corporation ANTI-EPHRIN B2 BLOCKER ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
CN115427060A (zh) 2020-02-19 2022-12-02 海必恩制药公司 环孢菌素类似物用于治疗纤维化的用途
JP2024543981A (ja) * 2021-12-01 2024-11-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性疾患の処置に使用するためのｉｒａｐアミノペプチダーゼ阻害剤の使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
JP2015509483A (ja) * 2012-02-06 2015-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 線維症を治療するためのｐｉ３ｋ阻害剤
WO2016179645A1 (en) * 2015-05-08 2016-11-17 Monash University 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1789079T3 (da) * 2004-09-09 2013-03-11 Florey Howard Inst Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf
MX2008002431A (es) * 2005-08-23 2008-04-03 Wyeth Corp Metodos para el tratamiento contra ansiedad y para identificacion de agentes ansioliticos.
US20150057216A1 (en) * 2011-12-16 2015-02-26 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
JP6327923B2 (ja) 2014-04-25 2018-05-23 旭化成株式会社 ポリアセタール樹脂組成物、及びそれからなる成形体
DE102014114090A1 (de) 2014-09-29 2016-03-31 Karlsruher Institut für Technologie Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion
US9519061B2 (en) * 2014-12-26 2016-12-13 Here Global B.V. Geometric fingerprinting for localization of a device
EP3328384B1 (en) * 2015-07-30 2020-07-29 Monash University Fibrotic treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
JP2015509483A (ja) * 2012-02-06 2015-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 線維症を治療するためのｐｉ３ｋ阻害剤
WO2016179645A1 (en) * 2015-05-08 2016-11-17 Monash University 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYPERTENSION, vol. 60, no. 2, JPN6019005382, 2012, pages 488 - 1, ISSN: 0004349402 *
J. MED. CHEM., vol. 53, JPN6019005385, 2010, pages 8059 - 8071, ISSN: 0004349403 *

Also Published As

Publication number Publication date
EP3328384A4 (en) 2019-03-06
JP7457360B2 (ja) 2024-03-28
SG11201808478RA (en) 2018-10-30
AU2016301113B2 (en) 2019-10-03
AU2016301113A1 (en) 2018-02-22
EP3328384B1 (en) 2020-07-29
CA3017028A1 (en) 2017-02-02
US20200362354A1 (en) 2020-11-19
US20210340547A1 (en) 2021-11-04
US20180223287A1 (en) 2018-08-09
US20240084308A1 (en) 2024-03-14
US20190249179A1 (en) 2019-08-15
US10100311B2 (en) 2018-10-16
CA3017028C (en) 2020-06-16
HK1256423A1 (zh) 2019-09-20
EP3328384A1 (en) 2018-06-06
US11834663B2 (en) 2023-12-05
WO2017015720A1 (en) 2017-02-02
US11078488B2 (en) 2021-08-03
JP2020189845A (ja) 2020-11-26
US10787668B2 (en) 2020-09-29
JP2023030022A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
JP7457360B2 (ja) 線維症の処置
JP7050751B2 (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
US10759788B2 (en) Pharmaceutical uses of pyridine carboxamide derivatives
CN106456795A (zh) 靶向治疗学
US20080139585A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
CA2918340C (en) Rhynchophylline derivatives and their use as epha4 inhibitors for neuroprotection
KR20180093930A (ko) 통각과민증을 치료하는 방법
JP2016514141A (ja) Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法
JP2021519312A (ja) カルパインモジュレーター及びその治療的使用
KR20210097100A (ko) 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도
CN108250058A (zh) Ppar激动剂及其在治疗老年痴呆及其他疾病中的用途
TWI869568B (zh) 新穎之氫醌衍生物
CN111494380B (zh) Db-1在制备防治nlrp3炎症小体相关疾病的药物中的应用及其药物组合物
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
AU2016259977A1 (en) 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
US20230159438A1 (en) Arylamides and methods of use thereof
MX2010012874A (es) Derivados de estirilbenzofurano como inhibidores de formacion de fibrilla beta-amiloide y metodo de preparacion de los mismos.
KR20230076685A (ko) 플라보논 유도체 화합물 및 이의 섬유증을 치료 또는 완화하기 위한 의약 용도
TW202504895A (zh) 新穎甲基喹唑啉酮衍生物
CN106220562A (zh) 两种喹啉环类药物的新用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190118

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190118

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200729

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200729

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200819

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200918

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200924

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210419

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210602

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210611

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210707

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210820